Growth Metrics

Kiniksa Pharmaceuticals International (KNSA) Consolidated Net Income (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Consolidated Net Income readings, the most recent being $22.6 million for Q1 2026.

  • On a quarterly basis, Consolidated Net Income rose 164.57% to $22.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $73.1 million, a 887.6% increase, with the full-year FY2025 number at $59.0 million, up 266.12% from a year prior.
  • Consolidated Net Income hit $22.6 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $14.2 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of $224.1 million in Q3 2022 to a low of -$90.6 million in Q4 2022.
  • Median Consolidated Net Income over the past 5 years was -$3.9 million (2024), compared with a mean of $2.4 million.
  • Biggest five-year swings in Consolidated Net Income: crashed 126.1% in 2024 and later surged 1269.6% in 2025.
  • Kiniksa Pharmaceuticals International's Consolidated Net Income stood at -$90.6 million in 2022, then increased by 8.39% to -$83.0 million in 2023, then skyrocketed by 98.54% to -$1.2 million in 2024, then surged by 1269.6% to $14.2 million in 2025, then skyrocketed by 59.11% to $22.6 million in 2026.
  • The last three reported values for Consolidated Net Income were $22.6 million (Q1 2026), $14.2 million (Q4 2025), and $18.4 million (Q3 2025) per Business Quant data.